ADPT Q3 2018 Earnings Report — Adaptive Biotechnologies Corporation Revenue & Financial Results | Market Cap Arena

Adaptive Biotechnologies CorporationADPT

Q3 2018 Earnings

Reported September 29, 2018

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	Q3 2018	Q2 2018	Q3 2017	QoQ Change	YoY Change
Revenue	$17M	$12M	—	48.6%	—
Op. Income	-$9M	-$13M	—	31.2%	—
Gross Margin	68.8%	56.4%	—	12.4pp	—
Net Margin	-48.2%	-108.0%	—	59.8pp	—
EPS (Diluted)	$-0.08	$-0.12	—	34.8%	—
Free Cash Flow	-$14M	-$10M	—	-37.6%	—

Income Statement

Item	Amount
REVENUE	$17M
Cost of Revenue	$5M
GROSS PROFIT	$12M
R&D Expenses	$10M
Selling & Marketing	$6M
General & Administrative	$5M
SG&A Expenses	$11M
Other Expenses	$428.0K
Operating Expenses	$21M
Cost & Expenses	$26M
OPERATING INCOME	-$9M
Interest Income	$869.0K
Interest Expense	$0
Other Income/Expenses	$869.0K
INCOME BEFORE TAX	-$8M
Income Tax Expense	$0
Net Income from Continuing Ops	-$8M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	-$8M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	-$8M
D&A	$1M
EBIT	-$9M
EBITDA	-$8M
EPS	-$0
EPS Diluted	-$0

Cash Flow Statement

Item	Amount
Net Income	-$8M
Depreciation & Amortization	$1M
Stock-Based Compensation	$3M
Deferred Income Tax	-$369.0K
Other Non-Cash Items	$1.0K
Change in Working Capital	-$7M
OPERATING CASH FLOW	-$12M
Capital Expenditure	-$2M
Acquisitions (Net)	$0
Purchases of Investments	-$26M
Sales/Maturities of Investments	$34M
Other Investing Activities	$7M
NET CASH FROM INVESTING	$5M
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$57.0K
NET CASH FROM FINANCING	$57.0K
FREE CASH FLOW	-$14M
Net Change in Cash	-$6M